Nicotinamide phosphoribosyltransferase (NAMPT) was first reported as a pre-B-cell colony enhancing factor in 1994 with little notice, but it has received increasing attention in recent years due to accumulating evidence indicating that NAMPT is a pleiotropic protein such as a growth factor, a cytokine, an enzyme and a visfatin. Now, NAMPT has been accepted as an official name of this protein. Because of NAMPTââ¬â¢s multiple functions in a variety of physiological processes, their dysregulations have been implicated in the pathogenesis of a number of human diseases or conditions such as acute lung injury, aging, atherosclerosis, cancer, diabetes, rheumatoid arthritis and sepsis. This review will cover the current understanding of NAMPTââ¬â¢s structure and functions with an emphasis on recent progress of nicotinamide phosphoribosyltransferaseââ¬â¢s pathological roles in various human diseases and conditions. Future directions on exploring its Terra incognita will be offered in the end. Shui Qing Ye, Nicotinamide Phosphoribosyltransferase in Human Diseases
Last date updated on September, 2024